HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer North America United States

Alcresta Infused With $10M Series B To Get First Product To Market

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.

You may also be interested in...



Alcresta Launches With Dynamic Business Model; Raises $10M Series A

Former Alnara executives have come together with the company’s previous investors to launch two start-ups focusing on enzyme therapies.

Alnara Execs Start Anew With Allena; $15 M Series A

Former Alnara founders Alexey Margolin and Robert Gallotto have begun a new venture that includes Alnara’s previous investors.

Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy

Alnara hopes to leverage Lilly's prior success with recombinant insulin products.

Table

View full table

Topics

Related Companies

Tags:
Consumer North America United States
Latest Headlines

Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'

Over The Counter 6 Jan 2023: Prebiotics And Consumer Health: Opportunity, Regulation and Future, With Clasado’s Per Rehné

US FDA Food Safety Overhaul Will Have Ripple Effects For Drug Inspections

Reorganization Of US FDA’s Office Of Regulatory Affairs Will Deliver More Preemptive Inspectorate

See All
UsernamePublicRestriction

Register

RS124396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By